Alkem Laboratories’ September-quarter revenue rose 13.8% while profit attributable to owners fell 11.7%, showing contrasting trends in results for the three months ended Sept. 30.
The company’s unaudited consolidated results filed with the Bombay Stock Exchange put profit attributable to owners at Rs 675.34 crore, compared with Rs 765.06 crore a year earlier. Total consolidated profit after tax was reported separately at Rs 667.13 crore, down 14.4% from Rs 779.11 crore. The filing presents these as distinct measures. Revenue from operations reached Rs 4,551.99 crore, up from Rs 4,000.99 crore.
Earnings before interest, tax, depreciation and amortization (EBITDA) came to Rs 1,025.19 crore, compared with Rs 920.77 crore, while its margin narrowed to 22.5% from 23%. Consolidated tax expense rose to Rs 331.9 crore from Rs 116.2 crore. The filing said the parent and one Indian subsidiary opted for the Section 115BAA tax regime for FY27, with current-period tax calculated at rates under that regime.
India sales rose 9.5% to Rs 3,027.5 crore, while international sales increased 22.3% to Rs 1,454 crore. U.S. sales grew 2.4% to Rs 783 crore; non-U.S. sales climbed 58% to Rs 671 crore. Alkem put non-U.S. growth at 28.6% excluding Occlutech. Managing Director Sandeep Singh said the company had “continued momentum” in India, citing execution across its acute and chronic portfolios.
Alkem said U.S. pricing pressure persisted in international markets, while higher volumes helped sustain the business. Non-U.S. sales include the period after Alkem Medtech acquired a majority stake in Occlutech Holding AG on July 16, 2026.
The board appointed Gopal Kothari as chief financial officer and key managerial personnel, effective Dec. 2.
